BridgeBio reported that infigratinib, an oral FGFR3 inhibitor, produced height gains comparable to Voxzogo in trials for achondroplasia while offering an oral dosing option. BioCentury’s reporting indicates the data could support upcoming regulatory submissions and expand treatment choices for patients and prescribers who prefer non-injectable regimens. BridgeBio’s readout positions an oral small-molecule approach directly against an established therapy and could reshape commercial dynamics in a rare pediatric indication where route of administration and ease of dosing affect uptake and long-term adherence.